Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 37, Issue -, Pages S148-S155Publisher
WILEY
DOI: 10.1002/eji.200737820
Keywords
cancer; immunotherapy; infection; vaccines
Categories
Ask authors/readers for more resources
Persistent infection by several microbial agents is responsible for at least 15% of cancer globally, including most cancers of the liver, stomach., and cervix. The recent development of vaccines that can prevent infection and premalignant disease caused by human papillomaviruses (HPV), which cause virtually all cases of cervical cancer as well as some other cancers, has focused renewed attention on infection control as a means of reducing the global cancer burden. For vaccines to prevent cancer-causing infection with hepatitis C virus, Helicobacter pylori, or Epstein Barr virus, new vaccine technologies to induce more effective protective responses are required. For the two available cancer control vaccines, designed to prevent infection with HPV and hepatitis B virus, the major challenge is to promote effective vaccine deployment through education programs and increased affordability/accessibility for underserved populations, particularly in the developing world, where the cancer burden attributable to infection by these two viruses is greatest.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available